WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Jing Wang
Associate
Patents and Innovations
New York
jiwang@wsgr.com

D212-497-7740

Download vCard
Open PDF

Dr. Jing Wang is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her practice focuses on strategic patent counseling, global patent portfolio development and management, and IP diligence on company-side and investor-side financings for life science companies. Jing regularly represents clients in the fields of genomics, proteomics, cancer immunology, gene therapy, nucleotide-based therapeutics, antibody-based therapeutics, cancer diagnostics, and nucleic acid and protein sequencing.

Prior to joining the firm, Jing completed her Ph.D. in Chemistry at Yale University, under James Rothman (2013 Nobel Laureate), where she studied cell biology, chemical biology, and nanotechnology.

Experience

Dr. Jing Wang is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her practice focuses on strategic patent counseling, global patent portfolio development and management, and IP diligence on company-side and investor-side financings for life science companies. Jing regularly represents clients in the fields of genomics, proteomics, cancer immunology, gene therapy, nucleotide-based therapeutics, antibody-based therapeutics, cancer diagnostics, and nucleic acid and protein sequencing.

Prior to joining the firm, Jing completed her Ph.D. in Chemistry at Yale University, under James Rothman (2013 Nobel Laureate), where she studied cell biology, chemical biology, and nanotechnology.

Education
  • J.D., Fordham University School of Law
  • Ph.D., Chemistry, Yale University
  • B.S., Chemistry, Case Western Reserve University
Admissions
  • State Bar of Connecticut
  • State Bar of New York
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., Fordham University School of Law
  • Ph.D., Chemistry, Yale University
  • B.S., Chemistry, Case Western Reserve University
Admissions
  • State Bar of Connecticut
  • State Bar of New York
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author with Y. Yang, H. Shigematsu, W. Xu, W. M. Shih, J.E. Rothman, and C. Lin, "Self-assembly of Size-Controlled Liposomes on DNA Nanotemplates," Nature Chemistry, 2016
  • Co-author with W. Xu, B. Nathwani, C. Lin, E. Karatekin, F. Pincet, W. Shih, and J.E. Rothman, "A Programmable DNA Origami Platform to Organize SNAREs for Membrane Fusion," 138(13) Journal of the American Chemical Society 4439-47, 2016
  • Co-author with J. Wang, O. Bello, S.M. Auclair, J. Coleman, F. Pincet, S.S Krishnakumar, C.V. Sindelar, and J.E. Rothman, "Calcium Sensitive Ring-like Oligomers Formed by Synaptotagmin," 111(38) Proceedings of the National Academy of Sciences 13966-71, 2014
  • Co-author with L. Shi, Q. Shen, A. Kiel, H. Wang, T.J. Melia, J.E. Rothman, and F. Pincet, "SNARE Proteins: One to Fuse and Three to Keep the Nascent Fusion Pore Open," 335(6074) Science 1355-9, 2012
Insights

Select Publications

  • Co-author with Y. Yang, H. Shigematsu, W. Xu, W. M. Shih, J.E. Rothman, and C. Lin, "Self-assembly of Size-Controlled Liposomes on DNA Nanotemplates," Nature Chemistry, 2016
  • Co-author with W. Xu, B. Nathwani, C. Lin, E. Karatekin, F. Pincet, W. Shih, and J.E. Rothman, "A Programmable DNA Origami Platform to Organize SNAREs for Membrane Fusion," 138(13) Journal of the American Chemical Society 4439-47, 2016
  • Co-author with J. Wang, O. Bello, S.M. Auclair, J. Coleman, F. Pincet, S.S Krishnakumar, C.V. Sindelar, and J.E. Rothman, "Calcium Sensitive Ring-like Oligomers Formed by Synaptotagmin," 111(38) Proceedings of the National Academy of Sciences 13966-71, 2014
  • Co-author with L. Shi, Q. Shen, A. Kiel, H. Wang, T.J. Melia, J.E. Rothman, and F. Pincet, "SNARE Proteins: One to Fuse and Three to Keep the Nascent Fusion Pore Open," 335(6074) Science 1355-9, 2012

Biological Sciences and Biotechnology

  • Antibody
  • Biologics
  • Cancer therapeutics
  • Cell therapy
  • Cellular immunology
  • Epigenetics
  • Genetics
  • Genomics
  • Molecular biology
  • Proteomics

Therapeutics and Drug Discovery

  • Drug conjugates
  • Gene editing
  • Gene therapy
  • Immunotherapy targets
  • Peptide therapeutics

Diagnostics and Medical Devices

  • Cancer diagnostics

Genomics and Data Analysis

  • Next-generation sequencing
  • Nucleic acid sequencing
  • Protein sequencing
  • Single-Cell sequencing
Technical Fluency

Biological Sciences and Biotechnology

  • Antibody
  • Biologics
  • Cancer therapeutics
  • Cell therapy
  • Cellular immunology
  • Epigenetics
  • Genetics
  • Genomics
  • Molecular biology
  • Proteomics

Therapeutics and Drug Discovery

  • Drug conjugates
  • Gene editing
  • Gene therapy
  • Immunotherapy targets
  • Peptide therapeutics

Diagnostics and Medical Devices

  • Cancer diagnostics

Genomics and Data Analysis

  • Next-generation sequencing
  • Nucleic acid sequencing
  • Protein sequencing
  • Single-Cell sequencing
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Portal Biotech on IP Matters Related to $35 Million Series A Financing
On June 30, 2025, Portal Biotech, a pioneering biotechnology company based in London, announced a $35 million Series A financing round—one of the largest investments in a life sciences tools company in Europe. The oversubscribed round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with participation from existing investors Science Creates Venture Capital, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank, and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Portal Biotech on IP diligence matters related to the transaction.
Learn More
Client Highlights
Firm Advises Novo Holdings on IP Matters Related to Oxford Nanopore Investment
On August 1, 2024, Novo Holdings, a leading international life science investor, announced a £50 million investment in Oxford Nanopore Technologies, a leading UK-listed company behind a new generation of molecular sensing technology based on nanopores, which is today used for DNA/RNA sequencing. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on IP diligence matters related to the transaction.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.